John Reed, J&J’s EVP of innovative medicine

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

John­son & John­son is lay­ing out its drug de­vel­op­ment am­bi­tions un­der its new R&D chief, pro­ject­ing that it will bring in bil­lions of dol­lars in added sales from new drugs in can­cer, im­munol­o­gy and oth­er ar­eas, as well as some high-risk bets in Alzheimer’s dis­ease.

The com­pa­ny shared the long-term pro­jec­tions as part of one of the busi­ness up­dates it holds every few years. J&J is fore­cast­ing that drug sales will grow 5% to 7% a year from 2025 to 2030, off a pro­ject­ed base of $57 bil­lion in 2025. And it’s promis­ing in­vestors 20 new drugs and 50 ex­pand­ed prod­ucts, in­clud­ing 10 with peak sales of $5 bil­lion or more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.